Company: SVREW
Filing Date: 2025-07-01
Form Type: F-1
Source: 0001213900-25-060400
Chunk: 21

Company: SaverOne 2014 Ltd.
Filing Date: 2025-07-01
Form: F-1
Chunk 21
---
, financial condition and results of
operations will be materially and adversely affected, and we may be unable to continue as a going concern.

<div align='center'>9</div>

We may not be able to continue complying with the continued Nasdaq listing requirements, which could result in delisting of the ADSs from Nasdaq.

We have in the past, and may
in the future, be unable to comply with certain of the listing standards that we are required to meet to maintain the listing of the ADSs
on Nasdaq.

On May 17, 2024, we received
notification from the Nasdaq Staff, indicating that, based on the closing bid price of the ADSs for the 30 consecutive business days,
we did not meet the Minimum Bid Price Requirement for continued listing on Nasdaq pursuant to Listing Rule 5550(a)(2). In accordance with
Nasdaq Listing Rule 5810(c)(3)(A), we had an initial period of 180 calendar days from the date of the notification letter, or until November
13, 2024, to regain compliance with the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement, on
October 28, 2024, the Company effected the change in the ADS ratio from one (1) ADS representing five (5) Ordinary Shares, to one (1)
ADS representing ninety (90) Ordinary Share (the “2024 Reverse Stock Split. On November 12, 2024, the Nasdaq Staff informed the
Company that it regained compliance with the Minimum Bid Price Requirement, based on the closing bid price of the Company’s ADS
of $1.00 per share between October 28 and November 11, 2024.

However,
on February 20, 2025, we received a new letter from the Nasdaq Staff, notifying us that the Company was not in compliance with the Minimum
Bid Price Requirement, because the price per share of our ADS was below $1.00 for 30 consecutive business days. Because we effected the
2024 Reverse Stock Split within the prior one-year period, under a recently amended Listing Rule 5810(c)(3)(A)(iv), we were not eligible
to receive any new compliance or a cure period by the Nasdaq Staff. Accordingly, our ADSs were subject to delisting from Nasdaq unless
we requested an appeal of this determination. We requested an appeal and a hearing date was set for April 10, 2025.

On